secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROTHENA CORP PUBLIC LTD CO (PRTA)
CIK:        0001559053
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001559053-24-000012
Event type: earnings
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prothena Q1 net loss $72.2M ($1.34/sh); cash $548.7M; guides FY 2024 cash burn $208-225M
--------------------------------------------------------------------------------

- Net loss $72.2M vs $46.9M YoY; revenue $0.1M vs $2.2M; R&D expenses $64.1M vs $44.8M.
- Cash, equivalents & restricted cash $548.7M (no debt); expects ~$405M year-end 2024.
- Phase 3 AFFIRM-AL (birtamimab) topline data expected 4Q24–2Q25; Phase 1 PRX012 update in 2024.
- Bristol Myers Squibb initiated Phase 2 for BMS-986446 (tau antibody) in early Alzheimer’s.
- Daniel G. Welch appointed independent director and Chair Designate; David Ford named Chief People Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1559053/000155905324000012/0001559053-24-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1559053/000155905324000012/prta-20240508.htm
  HTML page:      https://secwatch.observer/filing/0001559053-24-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer